The agency has stepped up its campaign against drugmakers' improper listing of patents in the FDA's Orange Book, which it ...
The antitrust cop says that the more than 300 patent listings stall generic competition, keeping prices high for diabetes drugs, inhalers and more. The Federal Trade Commission is challenging ...
The Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications ...
The Federal Trade Commission said it is challenging hundreds of alleged "junk" patents held by pharmaceutical companies for 20 brand-name drugs, including Novo Nordisk's blockbuster diabetes drugs ...
Federal antitrust officials have redoubled efforts to challenge what they see as improper pharma patent listings that delay the market entry of generic drugs. This week, the Federal Trade Commission ...
The FTC is investigating improper patent listings, including Novo Nordisk's Ozempic, which could impact shareholders. Novo Nordisk's GLP-1 agonists, including Ozempic, have become a significant ...
The Federal Trade Commission (FTC) sent warning letters to 10 drugmakers, including Novo Nordisk (NVO), Teva Pharmaceutical (NYSE:TEVA), and AstraZeneca (NASDAQ:AZN), on Tuesday over questionable ...
Boehringer Ingelheim, one of 10 companies sent a warning letter by the FTC disputing the accuracy of patent listings in the ...
The Federal Trade Commission is seemingly seeking to clear the path for generic versions of the weight loss drug Ozempic — but there will be a long road ahead before cheaper versions of the ...
Restaurants have added additional surcharges to cover rising operational costs, but California's "junk fee" bill will eliminate them starting in July Tetra Images/Getty Have you ever noticed an ...
The U.S. Federal Trade Commission expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings pertaining to 20 different brand-name treatments for ...